Alector Inc. (ALEC)
Summary
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript
Alector, Inc. (ALEC) Discusses Strategic Advances in Next Generation Neurodegeneration Therapies and Pipeline Developments Transcript
Alector Maps Brain-Delivery Pipeline for Alzheimer's, Parkinson's Therapies
Alector NASDAQ: ALEC outlined its strategy to advance brain-penetrant therapies for neurodegenerative diseases, highlighting an anti-amyloid beta antibody for Alzheimer's disease and two siRNA programs targeting tau and alpha-synuclein.
Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript
Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks Transcript
Alector Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 680 | $1,243.78 | $1,261.47 | $17.69 | 1.42% |
| NA Nizar Araji National Bank Of Canada /FI/ | 200 | $4,130 | $349 | -$3,781 | -91.55% |
| DS Danny Salinas Cantor Fitzgerald LP | 295,492 | $614,623.36 | $523,020.84 | -$91,602.52 | -14.9% |
| BG Bart Gancher Intech Investment Management LLC | 24,530 | $31,018.56 | $46,729.65 | $15,711.09 | 50.65% |
| KJD Kathryn J. Daniels Canada Pension Plan Investment Board | 183,200 | $292,223 | $348,080 | $55,857 | 19.11% |
Alector Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Andrew S. Fein HC Wainwright & Co. | 27,138.82 | $51,020.99 | $51,156.68 | $135.69 | 0.27% |
Alector Inc. (ALEC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Alector Inc. ever had a stock split?
Alector Inc. Profile
| Biotechnology Industry | Healthcare Sector | Arnon Rosenthal CEO | NASDAQ (NGS) Exchange | 014442107 CUSIP |
| US Country | 103 Employees | - Last Dividend | - Last Split | 7 Feb 2019 IPO Date |
Overview
Alector, Inc. is a pioneering clinical-stage biopharmaceutical company, dedicated to breaking new ground in the treatment of neurodegeneration diseases. Since its establishment in 2013, Alector has focused on developing innovative therapies that target key aspects of neurodegenerative disorders. The company is engaged in rigorous research and development efforts, leveraging its expertise in biotechnology to create solutions that could potentially transform the treatment landscape for conditions such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis, among others. Headquartered in South San Francisco, California, Alector is propelled by strategic collaborations with entities like Adimab, LLC, for antibody research and development, and GlaxoSmithKline plc, focusing on the development and commercialization of specific monoclonal antibodies targeting neurodegenerative diseases.
Products and Services
- AL001 - This promising drug candidate is in Phase III clinical trials and targets immune activity within the brain that has genetic connections to a variety of neurodegenerative disorders. AL001 has the potential to treat frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis by leveraging the immune system's role in these diseases.
- AL101 - Currently in Phase I clinical trials, AL101 represents Alector's commitment to expanding its portfolio of treatments across the spectrum of neurodegenerative diseases. Focusing primarily on Alzheimer's and Parkinson's diseases, AL101 is evaluated for its potential to modify the course of these challenging conditions.
- AL002 - This product candidate is in the midst of Phase II clinical trials, aimed specifically at treating Alzheimer's disease. By focusing on unique targets within the Alzheimer's disease pathology, AL002 stands as a testament to Alector's innovative approach to tackling this prevalent and debilitating condition.
Contact Information
